New drug cocktail aims to tame multiple myeloma
NCT ID NCT06768489
First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This early-stage trial is testing a new drug called JNJ-79635322 in combination with other myeloma treatments (daratumumab, lenalidomide, or pomalidomide) in 140 people with multiple myeloma. The main goal is to find a safe and effective dose and to see how well the body tolerates the combinations. Researchers will also look for early signs that the treatment is shrinking the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JNJ-79635322 (a drug given under the skin) combined with daratumumab (injected), and either lenalidomide or pomalidomide (pills)
- What this could lead to
- If successful, this could point toward a new combination treatment option for multiple myeloma that may help control the disease longer.
- What could go wrong
- This is an early Phase 1 trial with only 140 participants, so it is primarily testing safety and dosing. It is too soon to know if the combination will work better than existing treatments, and side effects are expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Calvary Mater Newcastle Hospital
RECRUITINGWaratah, 2298, Australia
-
Carmel Medical Center
RECRUITINGHaifa, 3436212, Israel
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Hadassah Medical Center
RECRUITINGJerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
RECRUITINGSalamanca, 37007, Spain
-
Hosp. Clinic de Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Monash Medical Centre
RECRUITINGClayton, 3168, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, 3000, Australia
-
Sheba Medical Center
RECRUITINGRamat Gan, 52621, Israel
-
St Vincents Hospital Melbourne
RECRUITINGFitzroy, 3065, Australia
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, 64239, Israel
-
UMC Utrecht
RECRUITINGUtrecht, 3584 CX, Netherlands
-
Universitair Medisch Centrum Groningen
RECRUITINGGroningen, 9713 GZ, Netherlands
-
VU Medisch Centrum
RECRUITINGAmsterdam, 1081 HV, Netherlands
-
Winship Cancer Institute Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Wollongong Hospital
RECRUITINGWollongong, 2500, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact